99 related articles for article (PubMed ID: 27300512)
1. Altered CXCL12 expression reveals a dual role of CXCR4 in osteosarcoma primary tumor growth and metastasis.
Neklyudova O; Arlt MJ; Brennecke P; Thelen M; Gvozdenovic A; Kuzmanov A; Robl B; Botter SM; Born W; Fuchs B
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1739-50. PubMed ID: 27300512
[TBL] [Abstract][Full Text] [Related]
2. Bone morphogenetic protein 9 overexpression reduces osteosarcoma cell migration and invasion.
Lv Z; Yang D; Li J; Hu M; Luo M; Zhan X; Song P; Liu C; Bai H; Li B; Yang Y; Chen Y; Shi Q; Weng Y
Mol Cells; 2013 Aug; 36(2):119-26. PubMed ID: 23807047
[TBL] [Abstract][Full Text] [Related]
3. CXCR4 and its ligand CXCL12 display opposite expression profiles in feline mammary metastatic disease, with the exception of HER2-overexpressing tumors.
Marques CS; Santos AR; Gameiro A; Correia J; Ferreira F
BMC Cancer; 2018 Jul; 18(1):741. PubMed ID: 30012106
[TBL] [Abstract][Full Text] [Related]
4. EPI-X4, a CXCR4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma models.
Sagini MN; Zepp M; Eyol E; Ali DM; Gromova S; Dahlmann M; Behrens D; Groeschel C; Tischmeier L; Hoffmann J; Berger MR; Forssmann WG
Peptides; 2024 May; 175():171111. PubMed ID: 38036098
[TBL] [Abstract][Full Text] [Related]
5. The development of potent, competitive CXCR4 antagonists for the prevention of cancer metastasis.
Hamshaw I; Cominetti MMD; Lai WY; Searcey M; Mueller A
Biochem Pharmacol; 2023 Dec; 218():115921. PubMed ID: 37956893
[TBL] [Abstract][Full Text] [Related]
6. PIM3 kinase promotes tumor metastasis in hepatoblastoma by upregulating cell surface expression of chemokine receptor cxcr4.
Marayati R; Julson J; Bownes LV; Quinn CH; Stafman LL; Beierle AM; Markert HR; Hutchins SC; Stewart JE; Crossman DK; Hjelmeland AB; Mroczek-Musulman E; Beierle EA
Clin Exp Metastasis; 2022 Dec; 39(6):899-912. PubMed ID: 36315303
[TBL] [Abstract][Full Text] [Related]
7. Adaptor proteins mediate CXCR4 and PI4KA crosstalk in prostate cancer cells and the significance of PI4KA in bone tumor growth.
Govindarajan B; Sbrissa D; Pressprich M; Kim S; Rishi AK; Vaishampayan U; Cher ML; Chinni SR
Sci Rep; 2023 Nov; 13(1):20634. PubMed ID: 37996444
[TBL] [Abstract][Full Text] [Related]
8. Targeting the CXCL12/CXCR4 pathway to reduce radiation treatment side effects.
Chaudary N; Hill RP; Milosevic M
Radiother Oncol; 2024 May; 194():110194. PubMed ID: 38447871
[TBL] [Abstract][Full Text] [Related]
9. New insights into the role of CXCR4 in prostate cancer metastasis.
Gladson CL; Welch DR
Cancer Biol Ther; 2008 Nov; 7(11):1849-51. PubMed ID: 18981717
[No Abstract] [Full Text] [Related]
10. Proteolytic inactivation of CXCL12 in the lungs and circulation of COVID-19 patients.
Cambier S; Beretta F; Pörtner N; Metzemaekers M; de Carvalho AC; Martens E; Kaes J; Aelbrecht C; Jacobs C; Van Mol P; Wauters E; Meersseman P; Hermans G; Marques RE; Vanaudenaerde B; Vos R; Wauters J; Gouwy M; Proost P
Cell Mol Life Sci; 2023 Jul; 80(8):234. PubMed ID: 37505242
[TBL] [Abstract][Full Text] [Related]
11. Establishment of humanised xenograft models as
Khamarudin F; Muhamad M; Johari Ibahim M; Wan Mohamad Zain WNI; Aziz MA; Adib Ridzuan NR; Ab-Rahim S
Immunother Adv; 2024; 4(1):ltae002. PubMed ID: 38826586
[TBL] [Abstract][Full Text] [Related]
12. Intrinsic epigenetic state of primary osteosarcoma drives metastasis.
Singh I; Rainusso N; Kurenbekova L; Nirala BK; Dou J; Muruganandham A; Yustein JT
bioRxiv; 2023 Nov; ():. PubMed ID: 38014160
[TBL] [Abstract][Full Text] [Related]
13. Reversing the PAI-1-induced fibrotic immune exclusion of solid tumor by multivalent CXCR4 antagonistic nano-permeator.
Dong J; Zhu C; Huang Y; Li Q; Li J; Wang Z; Wang Y; Zhou Z; Sun M
Acta Pharm Sin B; 2023 Jul; 13(7):3106-3120. PubMed ID: 37521859
[TBL] [Abstract][Full Text] [Related]
14. Correction: circPVT1 regulates medullary thyroid cancer growth and metastasis by targeting miR-455-5p to activate CXCL12/CXCR4 signaling.
Zheng X; Rui S; Wang XF; Zou XH; Gong YP; Li ZH
J Exp Clin Cancer Res; 2023 Nov; 42(1):299. PubMed ID: 37957678
[No Abstract] [Full Text] [Related]
15. Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response In Osteosarcoma.
Li B; Wang Z; Wu H; Xue M; Lin P; Wang S; Lin N; Huang X; Pan W; Liu M; Yan X; Qu H; Sun L; Li H; Wu Y; Teng W; Wang Z; Zhou X; Chen H; Poznansky MC; Ye Z
Cancer Res; 2018 Jul; 78(14):3938-3953. PubMed ID: 29735547
[TBL] [Abstract][Full Text] [Related]
16. IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis.
Gross AC; Cam H; Phelps DA; Saraf AJ; Bid HK; Cam M; London CA; Winget SA; Arnold MA; Brandolini L; Mo X; Hinckley JM; Houghton PJ; Roberts RD
JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135299
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal stroma: Role in osteosarcoma progression.
Cortini M; Avnet S; Baldini N
Cancer Lett; 2017 Oct; 405():90-99. PubMed ID: 28774797
[TBL] [Abstract][Full Text] [Related]
18. Osteoid cell-derived chemokines drive bone-metastatic prostate cancer.
Johnson CS; Cook LM
Front Oncol; 2023; 13():1100585. PubMed ID: 37025604
[TBL] [Abstract][Full Text] [Related]
19. A Subset of Osteosarcoma Bears Markers of CXCL12-Abundant Reticular Cells.
Sosa BR; Wang Z; Healey JH; Hameed M; Greenblatt MB
JBMR Plus; 2022 Mar; 6(3):e10596. PubMed ID: 35309866
[TBL] [Abstract][Full Text] [Related]
20. Osteosarcoma and Metastasis.
Sheng G; Gao Y; Yang Y; Wu H
Front Oncol; 2021; 11():780264. PubMed ID: 34956899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
